Head-to-head · WeighScore
Kina vs Tablet Health
The verdict
Kina takes it — 70.1/100 to 47.6/100.
Kina grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Kina is a menopause-care telehealth platform where GLP-1 is the weight-loss treatment, offered alongside HRT, peptide, and compounded options for menopause symptoms.
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | Kina | Tablet Health |
|---|---|---|
| WeighScore | 70.1/100 | 47.6/100 |
| Grade | C | C |
| Scorecard rank | #107 | #495 |
| Semaglutide | $179/mo (starting dose, plus a separate fee, compounded) | Not disclosed |
| Tirzepatide | $179/mo (starting dose, compounded) | Not disclosed |
| Coverage | Coverage not published | Coverage not published |
| Brand-name access | Compounded only | Compounded only |
| Oral / sublingual | Injection only | Yes |
Graded #107 · C
Strengths
- Menopause-specialized care — GLP-1 weight treatment alongside HRT, peptide, and compounded options for menopause symptoms
- Prescribed and monitored by named board-certified physicians at Arora Health & Aesthetics, with dose adjustments included
- Verifiable LegitScript certification (seal ID 50917967)
- GLP-1 from $179/month with $0 membership fees, FSA/HSA eligibility, free shipping, and cancel-anytime
- Compounded semaglutide and tirzepatide, 100% online with a roughly 2-minute intake
Where it loses points
- Compounded medications are not FDA-approved — not brand Wegovy, Ozempic, Zepbound, or Mounjaro
- Built for women navigating menopause — less tailored if that is not your situation
- A separate $50 physician consultation fee applies on top of the medication price
- The compounding pharmacy partner is not named, and the full list of served states is not published
Graded #495 · C
Strengths
- LegitScript Certified
- Four named compounding pharmacy partners (Pharmacy Hub, Epiq Scripts, Dr. TelX, Emerad), none with FDA warning letters
- Oral GLP-1 option for both semaglutide and tirzepatide — uncommon in compounded telehealth
- Mid-tier pricing starting $179–$299/mo across all four product variants
- No commitment — cancel anytime
Where it loses points
- States served not published — you must complete the intake quiz to learn eligibility
- No founder, CEO, medical director, or pharmacist-in-charge named anywhere
- No BBB profile found
- Its Queens NYC pharmacy is 'opening soon' — all dispensing currently routes through external partners
- FDA issued this company a warning letter dated 19 March 2025; the letter is public in FDA's warning-letter database
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.